Impact of frozen section on long‐term outcomes in robot‐assisted laparoscopic prostatectomy

Abstract

ObjectivesTo compare 1‐year functional and 5‐year oncological outcomes of men undergoing robot‐assisted laparoscopic prostatectomy (RALP) with neurovascular structure‐adjacent frozen‐section examination (NeuroSAFE) with those in men undergoing RALP without NeuroSAFE (standard of care [SOC]).Subjects and MethodsMen undergoing RALP in our centre between 1 January 2009 and 30 June 2018 were enrolled from a prospectively maintained database. Patients were excluded if they had undergone preoperative therapy or postoperative adjuvant therapy or were enrolled in clinical trials. Patients were grouped based on use of NeuroSAFE. Follow‐up was censored at 5 years. The primary outcome was difference in time to biochemical recurrence (BCR) on multivariable analysis, defined as prostate‐specific antigen (PSA) >0.2 ng/L on two consecutive measurements. Secondary outcomes were difference in 1‐year erectile dysfunction and incontinence.ResultsIn the enrolment period, 1199 consecutive men underwent RALP, of whom 1140 were eligible, including 317 with NeuroSAFE and 823 with SOC. The median PSA follow‐up was 60 months in both groups. Rates of 5‐year BCR were similar on Kaplan–Meier survival curve analysis (11% vs 11%; P = 0.9), as was time to BCR on multivariable Cox proportional hazards modelling (hazard ratio 1.2; P = 0.6). Compared with the SOC group at 1 year, the NeuroSAFE group had similar unadjusted rates of incontinence (5.1% vs 7.7%) and lower unadjusted impotence (57% vs 80%). On multivariable analysis, NeuroSAFE patients had equivalent risk of incontinence (odds ratio [OR] 0.59, 95% CI 0.17–1.6; P = 0.4) but significantly reduced risk of erectile dysfunction (OR 0.37, 95% CI 0.22–0.60; P < 0.001).ConclusionsFor men undergoing RALP, compared with SOC, NeuroSAFE patients had equivalent time to BCR and risk of 1‐year incontinence, and significantly lower risk of 1‐year erectile dysfunction.